5160-25-8

Basic information

• Product Name: 1,3,4,5,6-Penta-O-acetyl-2-O-methansulfonyl-myo-inosit
• CAS NO: 5160-25-8
• Molecular Weight: 468.436
• Mol File: 5160-25-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1,3,4,5,6-Penta-O-acetyl-2-O-methansulfonyl-myo-inosit(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4,5,6-Penta-O-acetyl-2-O-methansulfonyl-myo-inosit(5160-25-8)
• EPA Substance Registry System: 1,3,4,5,6-Penta-O-acetyl-2-O-methansulfonyl-myo-inosit(5160-25-8)

Safety Data

• Hazardous Substances Data: 5160-25-8(Hazardous Substances Data)

Upstream product

• 52389-41-0 1(3),3(1),4(6),5,6(4)-penta-O-acetyl-sn-myoinositol 
• 124-63-0 methanesulfonyl chloride 
• 87-89-8 D-myo-inositol 
• 13462-79-8 1⁽³⁾,4⁽⁶⁾,5,6⁽⁴⁾-tetra-O-acetyl-sn-myo-inositol 
• 6763-47-9 rac-1,2-O-cyclohexylidene-myo-inositol 
• 39110-61-7 3,4,5,6-tetra-O-acetyl-1,2-O-cyclohexylidene-myo-inositol 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.